Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Updated analysis with additional FU of EV 302 EV+P in 1st line advanced Bladder Cancer.
- PFS & OS benefit in all groups.
- Benefit in cisplatin eligible/ineligible.
- Safety consistent with prior analysis.
- mDOR close to 2 years.
